Monopar Therapeutics (MNPR) CEO Robinson acquired 6,002 shares
Insider transactions reported
Chandler Robinson (Chief Executive Officer at Monopar Therapeutics Inc., MNPR) reported that they acquired 6,002 shares, and gave up 1,759 shares at $31.70 to cover taxes or an exercise price on Mar 4, 2025. After these transactions the filing shows 63,091 shares held directly.
- Reporting person
- Robinson Chandler
- Role
- Chief Executive Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 4, 2025 | Exercise or conversion of a derivative (M) | Common Stock1 | +6,002 | - | - | 64,850 direct |
| Mar 4, 2025 | Shares withheld for taxes or exercise price (F) | Common Stock2 | -1,759 | $31.70 | $55.8K | 63,091 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 4, 2025 | Grant or award (A) | Stock OptionsOn 85,759 Common Stock3 | +85,759 | - | - | 85,759 direct |
| Mar 4, 2025 | Grant or award (A) | Restricted Stock UnitsOn 79,899 Common Stock4 | +79,899 | - | - | 104,777 direct |
| Mar 4, 2025 | Exercise or conversion of a derivative (M) | Restricted Stock UnitsOn 6,002 Common Stock1, 6 | -6,002 | - | - | 98,775 direct |
Holdings before and after
- Common Stock: 58,848 to 63,091 direct
- Stock Options: 0 to 85,759 direct
- Restricted Stock Units: 24,878 to 98,775 direct
Other positions listed
- Common Stock: 855,589 indirect, See Footnote
Footnotes from the filing
- 1. Represents shares acquired on vesting and settlement of restricted stock units.
- 2. Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- 3. 6,647 options vested on the grant date. Remainder of options vest 6/48ths on June 30, 2025, and 1/48th per month thereafter.
- 4. 6,002 restricted stock units vested on the grant date. Remainder of restricted stock units vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.
- 5. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 855,589 shares. Dr. Robinson disclaims beneficial ownership of the 855,589 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
- 6. Represents vesting of 6,002 restricted stock units on the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Transaction codes in this filing
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Robinson report in this MNPR Form 4?
Chandler Robinson (Chief Executive Officer at Monopar Therapeutics Inc., MNPR) reported that they acquired 6,002 shares, and gave up 1,759 shares at $31.70 to cover taxes or an exercise price on Mar 4, 2025. After these transactions the filing shows 63,091 shares held directly.
How many MNPR shares does Robinson hold after this filing?
The filing shows 63,091 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code M mean on an SEC Form 4?
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Historical context for MNPR
Earlier insider filings at MNPR
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Follow MNPR and get a push notification the moment its next story breaks.